Axicabtagene ciloleucel

Drug Profile

Axicabtagene ciloleucel

Alternative Names: Axi-cel; KTE-C19; KTE-C19 CAR

Latest Information Update: 17 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cabaret Biotech
  • Developer Genentech; Kite Pharma; National Cancer Institute (USA)
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action CD19 antigen modulators; Gene transference; T lymphocyte replacements; T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Chronic lymphocytic leukaemia; Acute lymphoblastic leukaemia; Follicular lymphoma; Mantle-cell lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Phase II Mantle-cell lymphoma
  • Phase I/II Acute lymphoblastic leukaemia
  • Phase I Leukaemia

Most Recent Events

  • 08 Aug 2017 KITE pharma has patent protection for CAR-T products (Eshhar CAR-T patent (U.S. Patent No. 7,,
  • 08 Aug 2017 Kite Pharma plans commercial launch of axicabtagene ciloleucel for Non-Hodgkin's lymphoma in USA in second half of 2017
  • 08 Aug 2017 Kite Pharma expects approval and plans launch of axicabtagene ciloleucel for Diffuse large B-cell lymphoma, Follicular lymphoma and Primary mediastinal B-cell lymphoma in Europe in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top